Cerulean Pharma Inc.,
a biopharmaceutical company focused on novel, intelligently designed, nanoparticle-based
drugs, announced today that Oliver S. Fetzer has been named as President and
Chief Executive Officer. He has also been elected to the Company's board of
directors. Dr. Fetzer will succeed Alan L. Crane, who has been named Chairman
of the board of directors.
Dr. Fetzer has a diverse background in biotechnology and healthcare. Most
recently, he was Senior Vice President, Corporate Development and Research and
Development at Cubist Pharmaceuticals. While at Cubist his responsibilities
included Corporate Development, Business Development, Drug Discovery Research,
Non-Clinical Development, Clinical Development, Chemical Development, Medical
Affairs and Program Management.
Prior to joining Cubist, Oliver served as a Managing Director and Partner at
the Boston Consulting Group in the firm's healthcare practice where he was responsible
for projects in strategy, operational effectiveness, and mergers and integration.
Dr. Fetzer worked at Bayer AG early in his career where he was involved in chemistry
and pharmaceutics. He is a director of Auxilium Pharmaceuticals (NASDAQ: AUXL)
and holds a Ph.D. in Pharmaceutical Sciences from the Medical University of
South Carolina and an MBA from Carnegie Mellon University. "I am very excited
about joining Cerulean" said Dr. Fetzer. "The opportunity to develop
a technology and grow a company with such broad implications for the pharmaceutical
industry and to do it with an absolutely world-class team is truly exceptional."
"We are extremely pleased that Oliver Fetzer will be assuming the role
of CEO at Cerulean," said Alan Crane, Chairman of the board of Cerulean.
"As we move our first products towards the clinic and further demonstrate
the power of our nanopharmaceutical platform, Oliver's leadership, strategic
and operational skills across science and business will be invaluable."
In addition to serving as Chairman of Cerulean, Mr. Crane will assume the role
of General Partner at Polaris Venture Partners, where he has been a Venture
Partner since 2002.